Abstract 29P
Background
Arising from the arachnoid villi cells, meningioma constitutes 35% of all the primary brain tumors. According to WHO, meningiomas can be classified into 3 grades i.e. WHO grade I (typical), WHO grade II (atypical), WHO grade III (anaplastic), further dividing them into 15 subtypes. Based solely on histology, nine of these subtypes comes under WHO grade I and three each in grade II and grade III. Though benign, 80% meningiomas can be treated by resection and chemotherapy thereafter. However, 20% recur and need further surgery, radiotherapy or another round of chemotherapy. Moreover, comorbidities like neurological and cognitive disorders can be caused by relatively indolent meningiomas. Impede cognition, in grade I patients further diminishes the life surviving conditions. Though, meningiomas are the most common intracranial tumors, occurrence of multiple meningioma (10% of the affected population) present another set of complications to deal with. Biomarkers as ‘targets’ may provide a better treatment and prognostic factors for these patients and their follow up routines.
Methods
Proteome studies that aim to decipher novel insights in the tumors provide a vast reservoir for likely molecular targets. However, non-availability of in depth proteomic re-searches in this field renders the treatment dubious. Herein, we present a proteome analysis of meningioma patients aimed to decipher the role of selected functional proteins which may serve to be target for therapies.
Results
The study presented here dwell on the proteins like adenylate kinase 2 (AK2), collagen type 1 alpha 1 (COL1A1)), plasminogen (PLG), found via mass spectrometry analysis. Simultaneously, cell sorting by FACS was used to support the mass spec findings.
Conclusions
Furthermore, these ‘protein markers’ might be targeted to identify another panel of proteins that can be screened in a large patient cohort using targeted proteomics.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Sir Ganga Ram Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract